A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma Intervention: Biological: BCMA/CD19 Dual-Target CAR-T Sponsors: Xijing Hospital; Gracell Biotechnology Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials